Obrixtamig clinical trials
Also written BI 764532.
How each study uses obrixtamig is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the obrixtamig studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
11 studies that test it; most in 2024 (4); 1 more planned to start later
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2023 | 2 |
| 2024 | 4 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 11 · Other 1
Boehringer Ingelheim (11) · Technische Universität Dresden (1)
Often tested with
Tested in the same studies.
Ezabenlimab (1) · Zocilurtatug Pelitecan (1) · Pumitamig (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 4
Studies that test obrixtamig.
- Dec 2026A Study to Test How BI 764532 is Taken up by Tumours in People With Small-cell Lung Cancer or Neuroendocrine CancerPhase 1 · Boehringer Ingelheim
- Mar 2027DAREON™-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With a Single Agent ChemotherapyPhase 1 · Boehringer Ingelheim
- Mar 2027DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung CancerPhase 1 · Boehringer Ingelheim
- Aug 2027A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3Phase 1 · Boehringer Ingelheim
Studies
Open first, then newest update. How each study uses obrixtamig is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 12
- DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine CancersRecruitingPhase 1/2Boehringer IngelheimNCT07707895Written as Obrixtamig
- A Study to Test Obrixtamig Treatment in People With Different Types of Advanced Cancer Who Took Part in a Previous Study With ObrixtamigNot yet recruitingPhase 3Boehringer IngelheimNCT07929051Written as Obrixtamig
- DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard ChemotherapyRecruitingPhase 3Boehringer IngelheimNCT07544654Written as Obrixtamig
- A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35)RecruitingPhase 1/2Boehringer IngelheimNCT07843940Written as Obrixtamig
- A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3RecruitingPhase 1Boehringer IngelheimNCT05916313Written as BI 764532
- A Study to Test How BI 764532 is Taken up by Tumours in People With Small-cell Lung Cancer or Neuroendocrine CancerRecruitingPhase 1Boehringer IngelheimNCT05963867Written as BI 764532
- A Trial for the Treatment of Advanced Large-Cell Neuroendocrine Cancer of the LungNot yet recruitingPhase 2Technische Universität DresdenNCT07561645Written as Obrixtamig
- DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine CancersRecruitingPhase 2Boehringer IngelheimNCT05882058Written as BI 764532, dose 1
- A Study to Test Different Doses of Obrixtamig in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3Active, not recruitingPhase 1Boehringer IngelheimNCT04429087Written as Obrixtamig - parenteral 1
- DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung CancerActive, not recruitingPhase 1Boehringer IngelheimNCT06077500Written as BI 764532
- A Study to Test How Well Different Doses of Obrixtamig (BI 764532) in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3Active, not recruitingPhase 1Boehringer IngelheimNCT05879978Written as Obrixtamig
- DAREON™-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With a Single Agent ChemotherapyActive, not recruitingPhase 1Boehringer IngelheimNCT05990738Written as BI 764532
Given beside what is tested · 2 — obrixtamig is usual care or a partner of the new treatment
- DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard ChemoimmunotherapyRecruitingPhase 3Boehringer IngelheimNCT07472517Written as obrixtamig
- DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine CancersActive, not recruitingPhase 1Boehringer IngelheimNCT06132113Written as BI 764532
What changed recently
From the registry's own updates since Oct 18, 2026.
Started recruiting1
Newly registered1
Codes
What other systems call obrixtamig · ClinicalTrials.gg INT018522
- UNII (FDA) Y09G7LIC1AOBRIXTAMIGOne source FDA
- NCI Thesaurus C177765ObrixtamigOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | Y09G7LIC1A | OBRIXTAMIG | One source FDA |
| NCI Thesaurus | C177765 | Obrixtamig | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.